Drugs for Neglected Diseases initiative - DNDi
Faria de Oliveira is a distinguished legal professional with extensive experience spanning over three decades. Currently serving as an Honorary Member of the Comissão Especial de Direito Lusófono at OAB - Ordem dos Advogados do Brasil since October 2022, Faria de Oliveira is also the founding partner at Faria de Oliveira Advogados, which has established a strong presence in São Paulo, Rio de Janeiro, and Lisbon, and collaborates with representatives across Brazil and internationally. Additional roles include Secretary General of CJLP - Comunidade de Juristas de Língua Portuguesa, member of the Academia Paulista de Direito, member of the direction at Casa do Brasil - Terras de Cabral, legal director at Jornal SegNews, and ambassador for Global Goodwill Ambassadors. Faria de Oliveira holds a law degree from Pontifícia Universidade Católica de São Paulo and has been actively involved in various organizations, including serving as a board member for Drugs for Neglected Diseases initiative and as President of CISEGUR.
This person is not in any teams
This person is not in any offices
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.